<code id='963ADAD33E'></code><style id='963ADAD33E'></style>
    • <acronym id='963ADAD33E'></acronym>
      <center id='963ADAD33E'><center id='963ADAD33E'><tfoot id='963ADAD33E'></tfoot></center><abbr id='963ADAD33E'><dir id='963ADAD33E'><tfoot id='963ADAD33E'></tfoot><noframes id='963ADAD33E'>

    • <optgroup id='963ADAD33E'><strike id='963ADAD33E'><sup id='963ADAD33E'></sup></strike><code id='963ADAD33E'></code></optgroup>
        1. <b id='963ADAD33E'><label id='963ADAD33E'><select id='963ADAD33E'><dt id='963ADAD33E'><span id='963ADAD33E'></span></dt></select></label></b><u id='963ADAD33E'></u>
          <i id='963ADAD33E'><strike id='963ADAD33E'><tt id='963ADAD33E'><pre id='963ADAD33E'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:knowledge    - browse:784

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge